MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze PFE →
    • FindStock Picks / Stock Screener
    • Value · PFEIntrinsic Value Calculator
    • Invest · PFEInvestment Case
    • Hold · PFE5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PFE stock logo

PFE

Pfizer Inc.

$28.89
0.06
 (0.21%)
Exchange:  NYSE
Market Cap:  164.669B
Shares Outstanding:  5.683B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Albert Bourla
Full Time Employees:  75000
Address: 
66 Hudson Boulevard East
New York City
NY
10001-2192
US
Website:  https://www.pfizer.com
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women’s health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

PFE full analysis

12/11/2026

Welcome back to MarketSnap. Here's the contradiction I can't let go of: Pfizer just hit a 52-week high, up about 15% over the past year — and yet over five years it has lost more than 40% while its own industry gained about 21%. So is this the turnaround finally arriving, or is that nearly 6% dividend yield luring investors into a value trap? Because right now, the market is rotating into defensives while the AI trade wobbles, and Pfizer…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
PFPFE logoPFEPfizer Inc.164.7B40.99.58.3%
NVNVO logoNVONovo Nordisk A/S184.4B10.912.330.2%
BMBMY logoBMYBristol-Myers Squibb Company129.7B14.09.914.9%
GIGILD logoGILDGilead Sciences, Inc.208.5B——28.0%
SNSNY logoSNYSanofi115.9B25.110.77.5%
CECELG-RI logoCELG-RIBristol-Myers Squibb Company Ce110.8B14.00.014.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/03 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue59,554,00063,627,00062,579,000
Gross Profit34,600,00045,776,00046,512,000
EBITDA9,557,00018,127,00016,783,000
Operating Income4,417,00014,938,00017,407,000
Net Income2,119,0008,031,0007,771,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets226,501,000213,396,0000
Total Liabilities137,213,000124,899,000-93,096,000
Total Stockholders Equity89,014,00088,203,00093,096,000
Total Debt70,845,00063,649,0000
Cash and Cash Equivalents2,853,0001,043,0000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow8,700,00012,744,0000
Capital Expenditure-3,907,000-2,909,0000
Free Cash Flow4,793,0009,835,0000
Net Income2,172,0008,051,0007,771,000
Net Change in Cash2,449,000-1,810,000-1,107,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)52,507,954.145Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)55,824,297.084Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)54,309,700Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)22,384,039.792Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)23,703,911.538Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)23,101,123.564Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)12,568,163.822Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)13,610,862.502Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)13,134,660.002Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)10,411,392.879Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)11,068,964.666Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)10,768,647.018Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.310Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)2.390Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.210Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)11Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
63.627B  ?P/S
 (TTM)
: 
2.59
?Net Income
 (TTM)
: 
8.02B  ?P/E
 (TTM)
: 
40.87
?Enterprise Value
 (TTM)
: 
225.516B  ?EV/FCF
 (TTM)
: 
19.13
?Dividend Yield
 (TTM)
: 
5.95%  ?Payout Ratio
 (TTM)
: 
242.8%
?ROE
 (TTM)
: 
4.6%  ?ROIC
 (TTM)
: 
8.26%
?Net Debt
 (TTM)
: 
46.516B  ?Debt/Equity
 (TTM)
: 
0.7
?P/B
 (TTM)
: 
1.85  ?Current Ratio
 (TTM)
: 
1.42

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
9.47Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Diversified non-COVID portfolio delivering operational growth. Q3 2026 revenue of $61.7B (per call summary) exceeded expectations, with non-COVID products up 7% operationally and launched/acquired products up 32%, driven by Eliquis, Padcev, and NURTEC. FY2025 revenue of $62.6B with a 73.4% gross margin (TTM) demonstrates strong underlying profitability despite post-pandemic normalization from the 2022 peak of $101.2B.
  • Attractive valuation relative to earnings trajectory. Forward P/E of 9.58x (FY2026E EPS $3.03) and 9.87x (FY2027E) sit well below the industry TTM average of 44.2x and Pfizer's own TTM P/E of 41.6x, which is distorted by depressed trailing earnings. A 5.85% dividend yield (TTM) with $1.72 annual payout provides substantial income support.
  • Low market-correlated risk and improving momentum. Beta of 0.276 offers defensive characteristics. Performance is positive across all horizons up to one year (+15.44% 1Y, +14.10% 6M), and the stock recently hit a 52-week high, with commentary noting valuation remains modest versus analyst expectations.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates PFE intrinsic value between $30.87 – $35.30 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate PFE Intrinsic Value

Common questions about PFE valuation

Is Pfizer Inc. (PFE) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Pfizer Inc. (PFE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PFE a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PFE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PFE’s P/E ratio?

You can see PFE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PFE?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PFE a good long-term investment?

Whether PFE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Pfizer Inc.

  • Pfizer Inc. intrinsic value calculatorEstimate what the business is worth
  • Pfizer Inc. 5-year outlookWhat has to go right, and what could go wrong
PFE

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.21
MarketSnap

Trading Metrics:

Open: 28.92   Previous Close: 28.83
Day Low: 28.62   Day High: 28.99
Year Low: 23.62   Year High: 31.44
Price Avg 50: 28.8   Price Avg 200: 26.97
Volume: 21.447M   Average Volume: 35.523M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
13-11-2026 14:15
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
12-11-2026 17:40
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
12-11-2026 09:42
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
10-11-2026 10:00
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
10-11-2026 06:00
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
08-07-2026 10:01
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze PFE →
    • FindStock Picks / Stock Screener
    • Value · PFEIntrinsic Value Calculator
    • Invest · PFEInvestment Case
    • Hold · PFE5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.